Sejin Lee is a health services researcher with interests in pharmaceuticals policy, cancer outcomes, and patient reported outcomes research. She received her PhD from the University of North Carolina at Chapel Hill in the Department of Health Policy and Management in 2022. Her dissertation examined treatment decision making and patterns of treatment in patients with advanced melanoma, focusing on immunotherapy and targeted therapy. Prior to her PhD program, she worked primarily in the global biopharmaceutical industry in a number of roles across clinical research, regulatory affairs, and healthcare analytics services. As a postdoctoral fellow at Penn, she is working on a project examining barriers, facilitators, and alternatives to confirming benefit after the FDA grants early drug approval.
